Is there published evidence for Burna AI's approach?

Yes, on the supporting clinical literature. Inter-rater agreement on adverse event attribution today: kappa 0.59 to 0.68 (Hong et al., 2020). Attribution change between investigator and central review: 31 to 36% (Hillman et al., JCO 2010). The FDA-NCI 2019 attribution workshop characterised the current state as sub-optimal, unreliable, and inefficient. Survival benefit with patient symptom self-reporting: 22.5 vs 14.9 months median OS (Denis et al., JAMA 2019). ER visit reduction with patient self-reporting: 34% vs 41% (Basch et al., J Clin Oncol 2016). Burna AI's own internal testing performance and the in-progress 1,200-chart accuracy study will be published through peer-reviewed venues.